Buparlisib Market was valued at USD 0.19 Billion in 2022 and is projected to reach USD 0.42 Billion by 2030, growing at a CAGR of 10.9% from 2024 to 2030.
The global Buparlisib market, driven by advancements in oncology and other therapeutic areas, has been witnessing substantial growth over recent years. As of 2024, the market is valued at approximately USD 300 million, and it is projected to grow at a compound annual growth rate CAGR of 8.5% from 2024 to 2032. This growth trajectory is attributed to the increasing demand for targeted therapies, particularly in oncology, where Buparlisib is being explored for its efficacy in treating various types of cancers, such as breast cancer, glioblastoma, and others.
Key factors driving growth include the increasing prevalence of cancer globally, rising awareness about targeted therapies, and continuous research into Buparlisib’s effectiveness in combination with other treatments. Furthermore, the advancements in biopharmaceutical research and development R&D and an improved understanding of cancer genetics and molecular biology are significantly contributing to the market’s expansion.
In addition, the continuous exploration of Buparlisib in clinical trials and its potential approval in new therapeutic areas are expected to provide substantial growth opportunities over the coming years. Technological innovations, especially in drug formulation and delivery, are further enhancing Buparlisib’s effectiveness and market penetration.
Get an In-Depth Research Analysis of the Global Buparlisib Market Size And Forecast [2025-2032]
Increasing Cancer Prevalence: With the rising global burden of cancer, there is an increasing demand for effective treatments, and Buparlisib, being a promising cancer therapeutic, is well positioned to address this need.
R&D Advancements: Continuous research and clinical trials focusing on Buparlisib’s potential in treating a variety of cancers are propelling its growth. New findings on its combination with other therapies further enhance its market prospects.
Targeted Therapies: The growing preference for personalized and targeted cancer treatments is significantly driving the demand for Buparlisib. Targeted therapies offer higher precision and fewer side effects compared to traditional chemotherapy, making them a preferred choice.
High Development Costs: The research, clinical trials, and regulatory approval processes for drugs like Buparlisib involve significant costs, which can be a barrier for many companies to enter the market.
Regulatory Challenges: Regulatory approvals for new therapies are time consuming and subject to stringent guidelines. This can delay the market introduction of Buparlisib and limit its availability in various regions.
Collaborations and Partnerships: Collaborative ventures between pharmaceutical companies, research institutions, and biotechnology firms offer significant opportunities to enhance the development and commercialization of Buparlisib.
Expanding Application Areas: As clinical trials continue, Buparlisib’s use may expand to treat other types of cancers or even other diseases, further broadening its market potential.
Oncology: The oncology segment is the largest and fastest growing segment in the Buparlisib market, as Buparlisib is primarily used for cancer treatments. It is particularly effective in targeting cancer cells through its PI3K inhibition mechanism, which has shown promising results in treating breast cancer and glioblastoma.
Neurology: Buparlisib is also being explored for its potential use in neurological diseases, especially those involving dysfunction in the PI3K signaling pathway. Ongoing research into its efficacy in conditions like glioblastoma is contributing to this segment’s growth.
Pharmaceutical Companies: Major pharmaceutical companies engaged in the production and distribution of Buparlisib contribute significantly to the market. These companies are focusing on developing new formulations and combination therapies to enhance the drug’s effectiveness.
Research Institutes: Research institutes play a vital role in conducting clinical trials and exploring new applications for Buparlisib. Their contribution to the development and advancement of Buparlisib therapies is crucial to the market’s growth.
North America: North America dominates the Buparlisib market, driven by the presence of key pharmaceutical companies, high healthcare spending, and advanced healthcare infrastructure. The region also leads in clinical research and trials, particularly in oncology.
Europe: Europe is another prominent region in the Buparlisib market, with a strong emphasis on research and development in cancer treatments. The approval of new therapies and advancements in biotechnology further enhance the market’s potential in this region.
Asia Pacific: The Asia Pacific region is expected to experience significant growth in the Buparlisib market due to the increasing cancer burden, improving healthcare infrastructure, and rising investments in the pharmaceutical sector.
Novartis AG: Novartis is one of the leading players in the Buparlisib market, with significant investments in oncology research and targeted therapies. The company is involved in the development of novel formulations of Buparlisib and exploring its combination with other cancer treatments.
Gilead Sciences: Gilead Sciences has been actively involved in the development of Buparlisib as part of its oncology pipeline. The company focuses on innovative cancer therapies and has made significant contributions to the growth of the Buparlisib market.
Merck & Co.: Merck is a key player in the oncology space, and the company is exploring the potential of Buparlisib in combination with other cancer treatments. Merck’s strategic initiatives and partnerships enhance its role in shaping the Buparlisib market.
Combination Therapies: A major trend in the Buparlisib market is the exploration of combination therapies. Research into combining Buparlisib with other targeted therapies or immunotherapies is gaining traction, offering enhanced efficacy and reduced side effects.
Personalized Medicine: As the demand for personalized medicine grows, Buparlisib’s potential in tailored treatments based on genetic profiling is being explored, further enhancing its market prospects.
AI and Data Analytics: The integration of artificial intelligence AI and data analytics in drug development is playing a crucial role in identifying the most promising therapeutic combinations and accelerating the clinical trial process for Buparlisib.
Supply Chain Disruptions: The global supply chain for pharmaceutical ingredients and raw materials faces disruptions, which can affect the availability of Buparlisib and increase production costs.
Regulatory Delays: The lengthy and complex regulatory processes in different regions can delay the market introduction of Buparlisib, impacting its global availability.
Enhanced Supply Chain Management: Improving supply chain resilience by adopting advanced logistics solutions and diversifying manufacturing bases can help mitigate disruptions and ensure the timely availability of Buparlisib.
Accelerated Regulatory Approvals: Collaborating with regulatory bodies to streamline approval processes for novel cancer therapies and implementing adaptive regulatory pathways can reduce delays and support faster market access.
The future of the Buparlisib market looks promising, with significant growth expected over the next 5 to 10 years. The increasing demand for personalized and targeted therapies, coupled with advancements in oncology research and drug development, will continue to drive market growth. Additionally, the expansion of Buparlisib’s applications beyond oncology into other therapeutic areas presents new opportunities for market diversification.
Key drivers such as the increasing cancer burden, advancements in molecular biology, and the growing emphasis on precision medicine will shape the evolution of the market. However, challenges like regulatory hurdles and pricing pressures need to be addressed to ensure sustained growth.
Which regions are leading the Buparlisib market? North America and Europe currently lead the Buparlisib market, with strong contributions from the pharmaceutical sector and advanced research facilities. However, the Asia Pacific region is expected to grow rapidly due to increasing healthcare investments.
What are the primary applications of Buparlisib? Buparlisib is primarily used in oncology, especially for treating breast cancer and glioblastoma, though it is also being investigated for other therapeutic areas like neurology.
What are the key challenges faced by the Buparlisib market? Challenges include supply chain disruptions, regulatory hurdles, and the high cost of drug development. These factors can impact market accessibility and growth.
Who are the
Selleck Chemicals
Abcam
BOC Sciences
Syd Labs
Santa Cruz Biotechnology
Cayman Chemical
BioVision
Shimadzu
Biosynth Carbosynth
Adooq Bioscience
Axon Medchem
TargetMol
Enzo Biochem
LGC
LKT Laboratories
InvivoChem
J&K Scientific
By the year 2030, the scale for growth in the market research industry is reported to be above 120 billion which further indicates its projected compound annual growth rate (CAGR), of more than 5.8% from 2023 to 2030. There have also been disruptions in the industry due to advancements in machine learning, artificial intelligence and data analytics There is predictive analysis and real time information about consumers which such technologies provide to the companies enabling them to make better and precise decisions. The Asia-Pacific region is expected to be a key driver of growth, accounting for more than 35% of total revenue growth. In addition, new innovative techniques such as mobile surveys, social listening, and online panels, which emphasize speed, precision, and customization, are also transforming this particular sector.
Get Discount On The Purchase of the Global Buparlisib Market Size And Forecast [2025-2032]
Growing demand for below applications around the world has had a direct impact on the growth of the Global Buparlisib Market
Research
Medical
Based on Types the Market is categorized into Below types that held the largest Buparlisib market share In 2023.
Min Purity Less Than 98%
Min Purity 98%-99%
Min Purity More Than 99%
Global (United States, Global and Mexico)
Europe (Germany, UK, France, Italy, Russia, Turkey, etc.)
Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)
South America (Brazil, Argentina, Columbia, etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
For More Information or Query, Visit @ Buparlisib Market Research Analysis
1. Introduction of the Global Buparlisib Market
Overview of the Market
Scope of Report
Assumptions
2. Executive Summary
3. Research Methodology of Verified Market Reports
Data Mining
Validation
Primary Interviews
List of Data Sources
4. Global Buparlisib Market Outlook
Overview
Market Dynamics
Drivers
Restraints
Opportunities
Porters Five Force Model
Value Chain Analysis
5. Global Buparlisib Market, By Type
6. Global Buparlisib Market, By Application
7. Global Buparlisib Market, By Geography
Global
Europe
Asia Pacific
Rest of the World
8. Global Buparlisib Market Competitive Landscape
Overview
Company Market Ranking
Key Development Strategies
9. Company Profiles
10. Appendix
About Us: Verified Market Reports
Verified Market Reports is a leading Global Research and Consulting firm servicing over 5000+ global clients. We provide advanced analytical research solutions while offering information-enriched research studies. We also offer insights into strategic and growth analyses and data necessary to achieve corporate goals and critical revenue decisions.
Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance using industrial techniques to collect and analyze data on more than 25,000 high-impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.
Contact us:
Mr. Edwyne Fernandes
US: +1 (650)-781-4080
US Toll-Free: +1 (800)-782-1768
Website: https://www.verifiedmarketreports.com/